Upstate Active Clinical Trials
Study Title:
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed OsteosarcomaWhat is the purpose of the study? (in Layman's terms, please describe the study)
Determine the feasibility of adding cabozantinib to standard MAP (high dose methotrexate, doxorubicin, and cisplatin) chemotherapy in patients with newly diagnosed metastatic osteosarcoma with a resectable primary tumor. Determine whether MAP chemotherapy plus cabozantinib results in more favorable event-free survival than MAP chemotherapy alone in patients with localized, resectable osteosarcoma. Determine whether MAP chemotherapy plus cabozantinib results in more favorable event-free survival than MAP chemotherapy alone in patients with metastatic, pelvic and unresectable osteosarcoma.Upstate Institutional Review Board (IRB) Number:
2024216Study/Protocol ID:
AOST2032Study Phase:
IIIPatient Age Group:
Adults and ChildrenPrincipal Investigator:
Melanie A ComitoWhat is involved if I participate?
- How long is the study?
Receive treatment for 16 months, but will be followed on study for 10 years. - Is transportation provided or reimbursed?
No - Is parking provided or reimbursed?
Yes - What tests and procedures are involved?
Blood draws, imaging, surgery, and radiation.
Where will the study take place?
Upstate Cancer Center & SUNY Upstate Medical UniversityOther Information:
N/AClinicalTrials.Gov ID:
NCT05691478For more information about this trial go to ClinicalTrials.Gov
Who can I contact for more information?
Name: Suzanne M Majewski
Phone: 315-464-7232
Email: [email protected]